US Pharma MarketingSide effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.
Source: BioPharma Dive